Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (16016)	8/31/2002 11:32:37 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Angry at underperformance>yes. Added a little in 4s. Generally holding to 1/3rd or former position and willing to increase or decrease depending on performance/non-performance of bpi platform. Hu-1124 continues to have value and take both management & investor attention. One thing for sure if no bpi and no hu-1124 >much smaller value. Dilution, much decreased value.

To: Robert K. who wrote (16016)	9/1/2002 1:40:37 AM
From: Bluegreen	Respond to of 17367

Bob, would it be better to hold off on buying shares of Xoma to see IF there is approval of Raptiva AND Neuprex???? Would it not be better still to see IF approval comes the sales figures for a few years and then make a decision to buy????

To: Robert K. who wrote (16016)	9/1/2002 9:57:27 AM
From: aknahow	Respond to of 17367

It is easy to complain about Xoma's management. I do it all the time. And yet, and yet, one has only to look at what happened to so many of the most favored biotech companies, not to speak of telcoms and other high tech stocks, to be made aware that Xoma management, far from screwing up has enhanced and strengthened the company. Sure we have those who perpetuate and even believe the string of failures myth. Xoma is much stronger today than it was five years ago. Much of the risk has been wrung out or at worst changed from one type of risk to a different type, that is more acceptable. Both you and I wanted progress with Neuprex and BPI yesterday, but Xoma told us years ago that the focus was on hu1124, aka Xanelim, aka Raptiva. Xoma management was right. Were would Xoma be today if the focus had remained on BPI and Neuprex? We don't know yet if Baxter is going to default on its' agreement. I am assuming it will, but we don't know. Management did not abandon Neuprex, it made what appeared to be a most rational decision to speed its' development without further expense to Xoma, while Xoma maintained a major stake in the product and had significant milestone products. Agreements do not always work out.